Breast Cancer: Josephine's Survivor Story

Patient Info: Josephine, Female, Under 40

As of October 2025, Josephine was cancer-free after melanoma in 2015 and breast cancer 2 years later, with breast cancer treatment including operations, chemotherapy, radiotherapy, and 5 years of anti-hormone therapy.

ER/PR/HER2-positive breast cancer: gallbladder, liver, lung, pleural, and bone metastases after incomplete adjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer. Gallbladder metastasis kept ER/PR/HER2 positivity and Ki-67 >40%; markers supported breast origin.

Metastatic Site: gallbladder, liver, lung/pleura, bone

The patient died 3 years and 10 months after lumpectomy after metastatic ER/PR/HER2-positive breast cancer involved the gallbladder, liver, lungs/pleura, and bones following incomplete adjuvant therapy and loss to surveillance.

PubMed CentralRead more →

Stage IV Invasive Lobular Carcinoma: Nikoo's Patient Story

Patient Info: Nikoo, Female, 40s | Stage IV

Biomarkers: BRCA1/2 negative; PIK3 mutation reported on liquid biopsy

Metastatic Site: Peritoneal/abdominal lining; abdominal lymph nodes

Nikoo had Stage I invasive lobular breast cancer in 2003 and developed Stage IV metastatic recurrence in 2022 after about 19 years. As of October 2025, she was living with metastatic lobular breast cancer, had moved through multiple systemic options, and was participating in a Phase 1 clinical trial.

The Patient StoryRead more →

Triple-negative metastatic breast cancer with pituitary metastasis: symptom relief after debulking

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Pituitary metastasis was triple-negative breast cancer with no HER2 amplification.

Metastatic Site: liver; bone/skull; right breast; left orbit/optic…

Transsphenoidal debulking relieved visual symptoms and 6-month MRI showed no pituitary recurrence, while known metastatic breast cancer at other sites remained part of her ongoing cancer course.

PubMed CentralRead more →

Stage IIA breast collision tumor: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Two breast tumor parts were ER-positive; one HER2-low/negative and one HER2-positive. BRCA testing was suggested but not done.

Four years after surgery, she remained disease-free after mastectomy, adjuvant chemotherapy, HER2-targeted therapy, and endocrine therapy.

PubMed CentralRead more →

Breast Cancer: Theresa's Survivor Story

Patient Info: Theresa, Female, 40s

Biomarkers: Hormone receptor-positive; exact receptors not fully specified

Theresa completed treatment for multiple cancers, including bilateral mastectomy/reconstruction for breast cancer and later excision plus 3 months of radiation for chest-wall recurrence. As of October 2025, she described being about 6 years out from the later recurrence, with no other cancer found on scans.

The Patient StoryRead more →

Hormone receptor-positive male breast cancer: spontaneous regression after biopsy and mastectomy

Patient Info: Anonymized, Male, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative; p63 staining confirmed myoepithelial cells in residual benign cystic lesion

Mastectomy and axillary clearance showed no residual invasive carcinoma or carcinoma in situ, with clear margins; he recovered well and began adjuvant tamoxifen because of the original ER/PR-positive biopsy.

PubMed CentralRead more →

Stage IV Breast Cancer: Dana's Patient Story

Patient Info: Dana, Female, 50s | Stage IV

Metastatic Site: Liver; bones; lymph nodes

As of October 2025, Dana was living with stable Stage IV metastatic breast cancer involving the liver, bones, and lymph nodes, controlled with targeted therapy and hormone blockers while also managing bipolar disorder and treatment-related mental health effects.

The Patient StoryRead more →

Paget disease, bilateral apocrine breast carcinomas, and primary breast follicular lymphoma after aromatase inhibition

Patient Info: Anonymized, Female, 70+

Biomarkers: Initial breast cancer was ER/PR-positive, HER2-negative. Later apocrine cancers were triple-negative with AR/ER-beta markers. Lymphoma had IgH::BCL2.

As of September 2025, she was alive 3 years after bilateral mastectomy and observation for Stage Ie follicular lymphoma, with no recurrence of either breast carcinoma or lymphoma.

PubMed CentralRead more →

Breast Cancer: Karin's Patient Story

Patient Info: Karin, Female, 50s

As of September 2025, Karin was living with recurrent incurable breast cancer, felt healthy and fit, and had chosen mastectomy with reconstruction, ovary removal, anti-hormone therapy, and complementary therapies after recurrence.

Stage I Breast Cancer: Angela's Patient Story

Patient Info: Angela George, Female, 40s | Stage I

Biomarkers: Not explicitly reported; Herceptin was given

As of September 2025, Angela was approaching 5 years from her Stage I breast cancer diagnosis, had completed bilateral mastectomy, chemotherapy, Herceptin, and oophorectomy, and remained on daily estrogen-reducing medication with oncology visits every 6 months; the source does not explicitly state NED.

Cleveland ClinicRead more →

Stage IV Breast Cancer: Maria's Patient Story

Patient Info: Maria, Female | Stage IV

Metastatic Site: Bone (spine, clavicle, rib, thigh bone, scapula);…

Maria initially had a clean PET scan after chemotherapy, surgery, radiation, and targeted/endocrine therapy, but later developed Stage IV metastatic breast cancer involving multiple bone sites, with lung and cervical-region involvement also described. As of September 2025, she remained on treatment and did not have an available clinical trial option.

The Patient StoryRead more →

Stage IIA male breast cancer: chemotherapy, mastectomy, endocrine therapy, and benign adrenal nodule

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative

Final breast cancer pathology was T1N1M0 / AJCC Stage IIA ER-positive, PR-positive, HER2-negative invasive ductal carcinoma; the suspicious adrenal lesion was removed in June 2025 and proved to be a benign adrenal adenoma.

PubMed CentralRead more →

Stage IIIB male encapsulated papillary breast cancer: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: ER-positive 100%; PR-positive 100%; HER2-negative / IHC 1+; p63 loss supported encapsulated papillary carcinoma; no neuroendocrine differentiation

Three years after diagnosis, he was clinically doing well without evidence of breast cancer recurrence after mastectomy, radiation, and tamoxifen.

PubMed CentralRead more →

Breast Cancer: Marissa's Survivor Story

Patient Info: Marissa Coreno, Female, Under 40

Biomarkers: Tumor biomarkers not reported; no apparent genetic predisposition for breast cancer

As of August 2025, Marissa was 31, had no sign of cancer, and remained on estrogen-blocking therapy planned for 10 years after chemotherapy, bilateral mastectomies, reconstruction, radiation, a CDK 4/6 inhibitor pill and a bisphosphonate.

Cleveland ClinicRead more →

Stage IV Breast Cancer: Linda's Patient Story

Patient Info: Linda Norman, Female, 60s | Stage IV

Metastatic Site: Bone: humerus/shoulder region

As of August 2025, Linda was 1 year into treatment for bone-metastatic breast cancer with letrozole, Verzenio, and bone-strengthening infusions; scans showed the tumor had not grown and bone scarring suggested healing.

Stage IIB HER2-positive apocrine breast carcinoma treated with chemotherapy, trastuzumab, radiation, and tamoxifen

Patient Info: Anonymized, Female, Under 40 | Stage II

Biomarkers: ER 80%; PR 5%; HER2-positive by HercepTest and FISH; Ki-67 15%; AR testing not performed

At 7 months of follow-up, the patient remained in remission, with no locoregional recurrence or distant metastasis reported.

PubMed CentralRead more →

Metastatic hormone receptor-positive breast cancer: palbociclib and fulvestrant during dialysis

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-negative; HER2 0 / HER2-negative; Ki-67 20.1%

Metastatic Site: lung, pleura, bone, right supraclavicular lymph node

As of August 2025, metastatic breast cancer had remained stable for 18 months on fulvestrant plus dialysis-adjusted palbociclib dosing, with hematologic toxicity managed through treatment interruptions, transfusion, and dose reduction.

PubMed CentralRead more →

Metastatic invasive lobular breast cancer with emergency surgery for bowel obstruction

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: peritoneum, ovaries, pelvic wall/pelvic mass, liver…

The patient had known metastatic invasive lobular breast cancer and recovered from emergency laparotomy for bowel obstruction, with discharge in stable condition on postoperative day 5.

PubMed CentralRead more →

Stage 3 breast cancer: complete pathological response to chemotherapy

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative

At 1-year follow-up, she remained free of breast cancer; a thyroid nodule found on CT had no malignancy on fine-needle aspiration.

PubMed CentralRead more →

Isolated adrenal metastasis from breast cancer: adrenalectomy and exemestane plus palbociclib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; GATA3-positive; CK7-positive; mammaglobin-positive; GCDFP-15 rare staining

Metastatic Site: right adrenal gland

After laparoscopic right adrenalectomy for isolated metastatic breast carcinoma, follow-up CT abdomen/pelvis and PET-CT showed no metastatic disease elsewhere; surveillance while on exemestane and palbociclib showed no recurrence so far.

PubMed CentralRead more →

ER/PR-positive breast cancer with separate solitary rib plasmacytoma: disease-free after breast and plasmacytoma treatment

Patient Info: Anonymized, Female, 60s

Biomarkers: Breast cancer: ER-positive, PR-positive, HER2-negative

More than 5 years after treatment, she remained disease-free with no recurrence of either ER/PR-positive breast cancer or the separate solitary rib plasmacytoma.

PubMed CentralRead more →

HER2-low lobular breast cancer with bone marrow involvement treated with T-DXd

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial surgical specimen: ER-positive; PR-negative; HER2-negative. Bone marrow relapse: breast cancer infiltration with low HER2 staining.

Metastatic Site: bone marrow

Two years after starting T-DXd, this patient remained free of bone marrow disease and continued the same treatment regimen.

PubMed CentralRead more →

HER2-low lobular breast cancer with bone marrow involvement responding to T-DXd

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial surgical specimen: ER-positive; PR-negative; HER2-negative. Bone marrow relapse: breast cancer infiltration with low HER2 staining.

Metastatic Site: bone marrow

Two years after starting T-DXd, this patient remained free of bone marrow disease and continued the same treatment regimen.

PubMed CentralRead more →